Dr. Reddy’s Laboratories saw a significant surge in its shares on Thursday, jumping 10% during afternoon trading while the overall market was facing downward pressure. The stock was priced at Rs 1,338.70, marking an increase of Rs 121.70 by 1:36 pm on the Bombay Stock Exchange (BSE), notably surpassing the performance of major market indices that were in negative territory.
This sharp rise positioned Dr. Reddy’s Laboratories among the top gainers on the Nifty 50 index at a time when both the Sensex and Nifty were experiencing notable declines.
The sudden increase in the company’s stock price did not have a specific immediate cause or corporate announcement during trading hours, indicating that the surge was likely influenced by a mix of industry-related and company-specific factors.
One of the key drivers behind this surge seems to be a robust buying interest in pharmaceutical stocks as investors shifted towards defensive sectors amidst a risk-averse market environment. During volatile market conditions, investors often redirect their investments towards pharmaceutical and healthcare companies due to their perceived stability compared to sectors like automotive, metals, IT, and financials.
This trend was evident on Thursday as other pharmaceutical companies also experienced gains, with Cipla witnessing a rise of over 4% and Sun Pharmaceutical Industries showing strength earlier in the trading session.
The recent spike in crude oil prices exceeding $100 per barrel and concerns related to the economic repercussions of the conflict in West Asia have heightened risk aversion among equity investors, making defensive sectors more appealing.
Dr. Reddy’s Laboratories stands out as a prominent liquid large-cap stock in the pharmaceutical sector with significant exposure to export markets, particularly the United States. The company could benefit from a weaker rupee, which enhances the value of its overseas earnings when converted into the local currency.
Furthermore, the stock might be attracting increased buying interest following a period of underperformance. With its previous close at Rs 1,217 and trading below its 52-week high of approximately Rs 1,379, the sharp rebound on Thursday suggests a potential catch-up in its performance.
Optimism surrounding the company’s obesity drug prospects could also be contributing to the positive sentiment. Reports indicate that Dr. Reddy’s Laboratories is nearing a brokerage target price, highlighting its early advantage in India’s GLP-1 segment with its DCGI-approved product Obeda.
Additionally, market participants will closely monitor whether the stock can maintain its gains above the Rs 1,330 level throughout the session. Any further developments in terms of exchange filings, analyst assessments, sector trends, and market volatility will provide additional insights into the driving forces behind the stock’s movement. Amidst ongoing uncertainties in the equity markets, pharmaceutical stocks like Dr. Reddy’s Laboratories are likely to remain in focus as preferred defensive options for investors.